Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for TransCode Therapeutics Inc. (RNAZ : NSDQ)

• Company Description    TransCode Therapeutics is an emerging RNA oncology company. Its platform of investigational drug candidates is dedicated to improving patient outcomes encompassing a variety of tumor types. The company's lead therapeutic candidate includes TTX-MC138. TransCode Therapeutics is based in BOSTON. Number of Employees: 12

• Price / Volume Information    Yesterday's Closing Price: $2.06 Daily Weekly Monthly 20 Day Moving Average: 86,194 shares Shares Outstanding: 16.93 (millions) Market Capitalization: $34.88 (millions) Beta: 1.16 52 Week High: $20.99 52 Week Low: $1.83 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -46.91% -46.67% 12 Week -62.34% -63.14% Year To Date -69.84% -73.25%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 6 Liberty Square #2382 - Boston,MA 02109 USA ph: 857-837-3099 fax: - alan.freidman@transcodetherapeutics.com http://www.transcodetherapeutics.com

• General Corporate Information    Officers Philippe P. Calais - Chairman and Chief Executive Officer Thomas A. Fitzgerald - Director and Chief Financial Officer Elizabeth Czerepak - Director Erik Manting - Director Magda Marquet - Director Peer Information - (-) - (-) - (-) - (-) - (-) - (-) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-DRUGS Sector: Medical CUSIP: 89357L501 SIC: 2834 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/13/26 Share - Related Items Shares Outstanding: 16.93 Most Recent Split Date: 5.00 (0.04:1) Beta: 1.16 Market Capitalization: $34.88 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $ Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $ Payout Ratio: Number of Estimates in the Fiscal Year Consensus: Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/13/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: - Price/Cash Flow: - Price / Sales: - EPS Growth vs. Year Ago Period: -45.14% vs. Previous Quarter: 66.31% Sales Growth vs. Year Ago Period: -% vs. Previous Quarter: -% ROE 06/30/26 - - 03/31/26 - -875.35 12/31/25 - -382.87 ROA 06/30/26 - -37.46 03/31/26 - -50.36 12/31/25 - -57.10 Current Ratio 06/30/26 - 1.97 03/31/26 - 3.11 12/31/25 - 6.29 Quick Ratio 06/30/26 - 1.97 03/31/26 - 3.11 12/31/25 - 6.29 Operating Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Net Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Pre-Tax Margin 06/30/26 - - 03/31/26 - - 12/31/25 - - Book Value 06/30/26 - -26.17 03/31/26 - 1.36 12/31/25 - 11.27 Inventory Turnover 06/30/26 - - 03/31/26 - - 12/31/25 - - Debt-to-Equity 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00 Debt-to-Capital 06/30/26 - - 03/31/26 - 0.00 12/31/25 - 0.00

Powered by Zacks Investment Research ©